Tuberculosis drug resistance comes full circle.
Reichman
Lee B
LB
New Jersey Medical School Global Tuberculosis Institute, Newark, NJ 07101, USA. reichmlb@umdnj.edu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial / Q000187:drug effects*; D006801:Humans; D015242:Ofloxacin / Q000627:therapeutic use*; D011008:Pneumococcal Infections / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use; D013019:South Africa; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014944:World Health Organization
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D015242:Ofloxacin; D012293:Rifampin